Apr 24 |
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase
|
Apr 9 |
3 Biotech Stocks to Dump Before They Go to Zero
|
Apr 1 |
Tonix Pharmaceuticals GAAP EPS of -$0.86, revenue of $3.78M
|
Apr 1 |
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
|
Mar 28 |
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
|
Mar 25 |
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
|
Mar 21 |
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
|
Mar 20 |
Tonix picks CMOs for potential launch of fibromyalgia drug
|
Mar 20 |
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
|
Mar 19 |
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
|